Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VRC01, VRC01LS, and VRC07-523LS in HIV-Exposed Infants
NCT02256631Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2015
- Primary completion
- Jun 2020
- Modality
- Anti-infectious Disease mAbs
- Countries
- 4
01
Overview
Phase 1, open-label trial of VRC01, VRC01LS and VRC07-523LS in human immunodeficiency virus infection (HIV) (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percentage of Participants Who Died, Percentage of Participants With an Occurrence of at Least One Grade 3 or Higher Adverse Event and 4 more. Started Jun 2015; status: completed.
02
Drugs
VRC01VRC01LSVRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02256631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256631.